A Review of Recent Safety Data on COVID-19 Booster Vaccines

SAP Partners | Health System / Oncology | <b>Providence St. Joseph Health</b>

Sophia Humphreys, PharmD, MHA, said data are continuing to evolve around the safety and recommendations of COVID-19 booster doses, especially for the vaccine from Pfizer and BioNTech.

In an interview with Pharmacy Times, Sophia Humphreys, PharmD, MHA, said data are continuing to evolve around the safety and recommendations of COVID-19 booster doses, especially for the vaccine from Pfizer and BioNTech.

In the interview, Humphreys discussed the difference between a third vaccine dose and a booster dose, which patients are considered to be immunocompromised by the CDC, and what she's hearing about a full vaccine approval for children ages 12 to 15. She also discussed the evolving data for Johnson & Johnson and Moderna's COVID-19 vaccines.